Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Reports: Johnson & Johnson

Pharmaceutical sales up 6% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

1Q Revenues: $17.5 billion (+1%)

1Q Earnings: $4.9 billion (+1%)

Comments: Pharmaceutical sales were $8.2 billion in the quarter, up 6%, with domestic sales up 13% and international sales down 3%. REMICADE sales were $1.8 billion in the quarter, up 11%. SIMPONI/SIMPONI ARIA sales were $390 million, up 30%. STELARA sales were $735 million, up 34%. INVEGA SUSTENNA/XEPLION/TRINZA sales were $513 million, up 25%. New product sales growth was negatively impacted by lower sales of OLYSIO/SOVRIAD (simeprevir) down 86% to $32 million due to competitive Hep C entrants. Growth in new products include IMBRUVICA with $261 million in sales, approved for certain B-cell malignancies; XARELTO (+29% to $567 million), an oral anticoagulant; and INVOKANA/INVOKAMET (+17% to $325 million), for the treatment of type 2 diabetes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters